Biocon gets CRL from USFDA for anti-cancer drug

The company, however, said it does not expect this CRL to impact the commercial launch timing of biosimilar Pegfilgrastim in the US.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news